Brooks Laboratories appoints Prashant Rathi as CEO effective June 1

Brooks Laboratories has appointed Mr. Prashant Rathi as its Chief Executive Officer, effective June 1, 2026. He will serve in the new role in addition to his existing position as Chief Financial Officer. The decision was taken by the Board of Directors following a recommendation from the Nomination and Remuneration Committee.

Mr. Rathi is a qualified Chartered Accountant, Company Secretary, and holds a Diploma in IFRS from ACCA, UK. He brings over 13 years of experience in accounting, finance, and financial management. He has been associated with Brooks Laboratories for more than five years.

Details of Appointment

The company disclosed the appointment details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure references SEBI Master Circular No. SEBIHO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Particulars	Details
Name and Designation	Mr. Prashant Rathi, Chief Executive Officer (CEO) in addition to Chief Financial Officer (CFO)
Reason for Change	Appointment
Date of Appointment	June 1, 2026
Brief Profile	Qualified CA, CS, and Diploma in IFRS holder with over 13 years of experience in accounting and finance. Associated with the company for over five years.

During his tenure, Mr. Rathi has developed an understanding of the company's business operations, financial systems, and internal processes. The company stated that his expertise and familiarity with its affairs position him to contribute effectively towards future growth and long-term objectives.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+4.99%	+27.58%	+16.46%	-32.93%	-49.78%	-29.81%

Brooks Laboratories Limited has scheduled a meeting of its Board of Directors for Friday, May 29, 2026. The primary agenda of the meeting is to consider and approve the audited standalone and consolidated financial results of the company for the quarter and year ended March 31, 2026.

Board Meeting Agenda

The board will review the financial performance for the fiscal year ending March 31, 2026. This meeting is being convened in compliance with Regulation 29 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Trading Window Closure

Pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the company's Code of Conduct for Prevention of Insider Trading, the trading window for all Directors, Designated Persons, and their immediate relatives has been closed since April 1, 2026. This closure applies to dealing in the securities of the company.

The trading window will remain closed until 48 hours after the declaration of the audited financial results. This measure is intended to ensure compliance with regulatory standards regarding insider trading during the period of financial result announcements.

The intimation regarding the board meeting was officially communicated to the stock exchanges on May 22, 2026.